RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • October 4th, 2023 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd. Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually, as a “Party” or, collectively, as “Parties.”
JOINT CLINICAL COLLABORATION AGREEMENTJoint Clinical Collaboration Agreement • October 4th, 2023 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New District, Shanghai, China; and ArriVent BioPharma, Inc. (“ArriVent”), a Delaware corporation, at 18 Campus Blvd. Suite 100, Newport P.A. (each a Party; collectively, Parties.)
GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd.Global Technology Transfer and License Agreement • October 4th, 2023 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
This GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”) is effective from the Effective Date by and between:
